Saturday, 7 April 2012
Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
Abstract: The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFNγ production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, IL12
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment